TNP-470 (AGM-1470): Mechanisms of action and early clinical development

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2520-2527

  Castronovo, V ^a   Belotti, D ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; BROMOCRIPTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; MINOCYCLINE; MITOMYCIN C; TAMOXIFEN;

ANGIOGENESIS; CARCINOMA; CELL PROLIFERATION; CLINICAL TRIAL; DRUG METABOLISM; DRUG STRUCTURE; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MELANOMA; PRIORITY JOURNAL; REVIEW; SARCOMA; T LYMPHOCYTE; TUMOR CELL;

EID: 0030498706     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00388-7     Document Type: Article

References (55)

1. 1. Folkman, J. Angiogenesis: initiation and modulation. Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. Nicolso 1984, 201-8.
2. 2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992, 267, 10931-10934.
3. 3. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971, 133, 275-288.
4. 4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285, 1182-1186.
5. 5. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972, 175, 409-416.
6. 6. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [see comments]. N Engl J Med 1995, 333, 1757-1763.
7. 7. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
8. 8. McCowen MC, Callender ME, Lawlis JF. Fumagillin (H-3), a new antibiotic with amebicidal properties. Science 1951, 113, 202-203.
9. 9. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the Fumagillin Parent. Biochem Biophys Res Commun 1991, 174, 1070-1076.
10. 10. Hori A, Ikeyama S, Sudo K. Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM 1470) in vascular endothelial cells. Biochem Biophys Res Commun 1994, 204, 1067-1073.
11. 11. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994, 69, 212-216.
12. 12. Antoine N, Greimers R, De Roanne C, et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of cell cycle. Cancer Res 1994, 54, 2073-2076.
13. 13. Abe J, Zhou W, Takuwa N, et al. Fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994, 54, 3407-3412.
14. 14. Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994, 58, 439-451.
15. 15. Berger AE, Dortch KA, Staite ND, Mitchell MA, Evans BR, Holm MS. Modulation of T lymphocyte function by the angiogenesis inhibitor AGM-1470. Agents Actions 1993, 39, 86-88.
16. 16. Antoine N, Bours V, Heinen E, Simar LJ, Castronovo V. Stimulation of human B-lymphocyte proliferation by AGM-1470, a potent inhibitor of angiogenesis. J Natl Cancer Inst 1995, 87, 136-139.
17. 17. Antoine N, Daukandt M, Heinen M, Simar LJ, Castronovo V. In vitro and in vivo stimulation of the murine immune system by AGM-1470, a potent angiogenesis inhibitor. Am J Pathol 1996, 148, 393-398.
18. 18. Schoof DD, Obando JA, Cusack JCJ, Goedegebuure PS, Brem H, Eberlein TJ. The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int J Cancer 1996, 55, 630-635.
19. 19. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993, 53, 5233-5236.
20. 20. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 1994, 34, 869-875.
21. 21. Egawa S, Tsutsumi M, Konishi M, et al. The role of angiogenesis in the tumor growth of syrian hamster pancreatic cancer cell line HPD-NR. Gastroenterology 1995, 108, 1526-1533.
22. 22. Morita T, Shinoara N, Tokue A. Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma. Br J Urol 1994, 74, 416-421.
23. 23. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993, 53, 2566-2570.
24. 24. Pluda JM, Wyvill K, Figg WD, et al. A phase 1 study of an angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients (PTS) with HIV-associated Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 1994, 13, abstract no. 8.
25. 25. Placidi L, Cretton-Scott E, Desousa G, Rahmani R, Placidi M, Sommadossi JP. Disposition and metabolism of the angiogenic moderator O-(chloroacetylcarbamoyl) fumagillol (TNP-470, AGM-470) in human hepatocytes and tissue microsomes. Cancer Res 1995, 55, 3036-3042.
26. 26. Moore JD, Sommadossi JP. Determination of O-chloroacetyl-carbamoyl)fumagillol (TNP-470-AGM1470) and two metabolites in plasma by high-performance liquid chromatography mass spectrometry with atmospheric pressure chemical ionization. Mass Spectrometry 1995, 30, 1707-1715.
27. 27. Cretton-Scott E, Placidi L, McClure H, Anderson DC, Sommadossi JP. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl)fumagillol (TNP-470, AGM-1470) in Rhesus monkeys. Cancer Chemother Pharm 1996, 38, 117-122.
28. 28. Kamei S, Okada H, Inoue Y, Yoshioka T, Ogawa Y, Toguchi H. Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exp Ther 1993, 264, 469-474.
29. 29. Yanai S, Okada H, Misaki M, et al. Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver. J Pharmacol Exp Ther 1994, 271, 1267-1273.
30. 30. Yanai S, Okada H, Saito K, et al. Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma. Pharm Res 1995, 12, 653-657.
31. 31. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 1993, 53, 4262-4267.
32. 32. Takechi A. Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats. Neurol Med Chir 1994, 34, 729-733.
33. 33. Takechi A, Uozomi T, Kawamoto K, Ito A, Kurisu K, Sudo K. Inhibitory effect of TNP-470, a new anti-angiogenic agent on the estrogen induced rat pituitary tumors. Anticancer Res 1994, 14, 157-162.
34. 34. O'Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 1995, 30, 325-330.
35. 35. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. J Pediatr Surg 1993, 28, 445-451.
36. 36. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K, Uchida A. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1995, 61, 148-152.
37. 37. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996, 93, 2002-2007.
38. 38. Wilson JT, Penar PL. The effect of AGM-1470 in an improved intracranial 9L gliosarcoma rat model. Neurol Res 1994, 16, 121-124.
39. 39. Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993, 78, 470-476.
40. 40. McLeskey SW, Zhang L, Kharbanda S, et al. Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat 1996, 39, 103-117.
41. 41. McLeskey SW, Zhang L, Trock BL, et al. Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br J Cancer 1996, 73, 1053-1062.
42. 42. Yano T, Tanase M, Watanabe A, et al. Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice. Anticancer Res 1995, 15, 1355-1358.
43. 43. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995, 55, 836-839.
44. 44. Konno H, Tanaka T, Matsuda I, et al. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 1995, 61, 268-271.
45. 45. Nishimura Y, Murata R, Hiraoka M. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer 1996, 73, 270-274.
46. 46. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994, 57, 920-925.
47. 47. Voest EE, Kenyon BM, O'Reilly M, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87, 581-586.
48. 48. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995, 36, 227-236.
49. 49. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994, 54, 5143-5147.
50. 50. Peacock DJ, Banquerigo ML, Brahn E. A novel angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992, 175, 1135-1138.
51. 51. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol 1995, 160, 178-184.
52. 52. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol. Cell Immunol 1994, 157, 291-299.
53. 53. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995, 166, 196-206.
54. 54. Zukiwski J, Gutterman J, Bul C, et al. Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients (Pts) with androgen independent prostate cancer (AI PCa). Proc Am Soc Clin Oncol 1994, 13, abstract no. 795.
55. 55. Levy T, Kudelka A, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advance squamous cell cancer of the cervix. Proc Am Assoc Cancer Res 1996, 37, abstract no. 1140.